ASND
Ascendis Pharma A/SNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-75.04
P/S
17.01
EV/EBITDA
-154.53
DCF Value
$-4,838.78
FCF Yield
0.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.3%
Operating Margin
-19.0%
Net Margin
-31.7%
ROE
127.5%
ROA
-17.5%
ROIC
-19.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $245.2M | $-33.2M | $-0.54 |
| FY 2025 | $691.7M | $-219.0M | $-3.62 |
| Q3 2025 | $213.6M | $-61.0M | $-1.00 |
| Q2 2025 | $158.0M | $-38.9M | $-0.82 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
DK
Exchange
NASDAQ
Beta
0.48
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.